期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期胃癌及胃食管交界癌的免疫治疗现状及进展 被引量：3

Research status and progress in the immunotherapy of advanced gastric cancer and gastroesophageal junction carcinoma
原文传递
导出
摘要 PD-1/PD-L1抑制剂在晚期胃癌(GC)及胃食管交界癌(GEJC)的临床试验中显示出较好的疗效及安全性,为其临床应用提供了有力的科学依据。单药PD-1/PD-L1抑制剂治疗的疗效欠佳,仅作为后线治疗选择。PD-1/PD-L1抑制剂联合多种治疗模式能够提高患者的疾病应答率和延长患者生存时间,成为目前GC及GEJC治疗的热点。本文基于最新临床试验结果,对晚期GC及GEJC的免疫治疗疗效及预测分子进行综述。
作者 周莉(综述) 刘亮 任秀宝(审阅) ZHOU Li;LIU Liang;REN Xiubao
机构地区 天津医科大学肿瘤医院生物技术研究室
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2021年第10期1041-1048,共8页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.81702702)。
关键词 胃癌 免疫治疗 靶向治疗 化疗
分类号 R730.54 [医药卫生—肿瘤] R735 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献32

  • 1Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, FleigWE. Chemotherapy in advanced gastric cancer: a systematic reviewand meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909 [PMID: 16782930].
  • 2Van Cutsem E, Haller D, Ohtsu A. The role of chemotherapy in thecurrent treatment of gastric cancer. Gastric Cancer 2002; 5 Suppl 1:17-22 [PMID: 12772882].
  • 3Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L,Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G,Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumabin combination with chemotherapy versus chemotherapy alone fortreatment of HER2-positive advanced gastric or gastro-oesophagealjunction cancer (ToGA): a phase 3, open-label, randomisedcontrolled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI:10.1016/S0140-6736(10)61121-X].
  • 4Park SH. Second-line chemotherapy for patients withoesophagogastric adenocarcinoma. Lancet Oncol 2014; 15: 8-10[PMID: 24332239 DOI: 10.1016/S1470-2045(13)70580-1].
  • 5Ji SH, Lim do H, Yi SY, Kim HS, Jun HJ, Kim KH, Chang MH,Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY,Kang WK. A retrospective analysis of second-line chemotherapy inpatients with advanced gastric cancer. BMC Cancer 2009; 9: 110[PMID: 19358705].
  • 6Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S,Charalambous H, Koukouma A, Chau I, Cunningham D. Docetaxeland irinotecan as second-line therapy for advanced oesophagogastriccancer. Eur J Cancer 2011; 47: 1146-1151 [PMID: 21269822 DOI:10.1016/j.ejca.2010.12.021].
  • 7Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy foradvanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17: 81-90 [PMID: 15830569].
  • 8Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, HinkeA, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, ReichardtP. Survival advantage for irinotecan versus best supportive care assecond-line chemotherapy in gastric cancer--a randomised phaseIII study of the Arbeitsgemeinschaft Internistische Onkologie(AIO). Eur J Cancer 2011; 47: 2306-2314 [PMID: 21742485 DOI:10.1016/j.ejca.2011.06.002].
  • 9Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, HwangIG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY,Kang WK, Park SH. Salvage chemotherapy for pretreated gastriccancer: a randomized phase III trial comparing chemotherapyplus best supportive care with best supportive care alone. J ClinOncol 2012; 30: 1513-1518 [PMID: 22412140 DOI: 10.1200/JCO.2011.39.4585].
  • 10Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY,Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW,Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N,Blazeby JM, Dunn JA. Docetaxel versus active symptom controlfor refractory oesophagogastric adenocarcinoma (COUGAR-02): anopen-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15: 78-86 [PMID: 24332238 DOI: 10.1016/S1470-2045(13)70549-7].

共引文献131

同被引文献33

引证文献3

二级引证文献1

中国肿瘤生物治疗杂志
2021年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部